false 0001603207 0001603207 2024-01-30 2024-01-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 30, 2024

 

NOTABLE LABS, LTD.

(Exact name of registrant as specified in charter)

 

Israel   001-36581   Not Applicable
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

320 Hatch Drive
Foster City, California
  94404
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (415) 851-2410

 

N/A

(Former name or former address, if changed since last report)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value NIS 0.35 each   NTBL   The Nasdaq Capital Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 4.01.Changes in Registrant’s Certifying Accountant.

 

Dismissal of Independent Registered Public Accounting Firm

 

On January 30, 2024, Notable Labs, Ltd. (the “Company”) dismissed Kesselman & Kesselman C.P.A.s, a member of PricewaterhouseCoopers International Limited, effective immediately, as its independent registered public accounting firm (after receiving approval of the Audit Committee of the Company’s Board of Directors).

 

Kesselman & Kesselman C.P.A.’s reports on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2022 and December 31, 2021 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

 

During the Company’s fiscal years ended December 31, 2022 and December 31, 2021 and the subsequent interim period through January 30, 2024, (i) there were no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K, between the Company and Kesselman & Kesselman C.P.A.s on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, any of which that, if not resolved to Kesselman & Kesselman C.P.A.’s satisfaction, would have caused Kesselman & Kesselman C.P.A.s to make reference to the subject matter of any such disagreement in connection with its reports for such years and interim period, and (ii) there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K.

 

The Company provided Kesselman & Kesselman C.P.A.s with a copy of the above disclosures and requested that Kesselman & Kesselman C.P.A.s furnish a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made herein. A copy of Kesselman & Kesselman C.P.A.s letter dated February 2, 2024 is filed as Exhibit 16.1 to this Current Report on Form 8-K.

 

Newly Engaged Independent Registered Public Accounting Firm

 

On January 30, 2024, the Company engaged, subject to customary intake procedures and stockholder approval under applicable Israeli law, WithumSmith+Brown, PC as the Company’s new independent registered public accounting firm for the fiscal year ended December 31, 2023 (after receiving approval of the Audit Committee of the Company’s Board of Directors).

 

During the Company’s fiscal years ended December 31, 2022 and December 31, 2021 and the subsequent interim period through January 30, 2024, neither the Company nor anyone on its behalf has consulted with WithumSmith+Brown, PC regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that WithumSmith+Brown, PC concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
16.1   Letter from Kesselman & Kesselman C.P.A.s addressed to the Securities and Exchange Commission dated February 2, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NOTABLE LABS, LTD.
   
Date: February 2, 2024 By: /s/ Thomas A. Bock
  Name: Thomas A. Bock
  Title: Chief Executive Officer

 

 

 

Exhibit 16.1

 

February 2, 2024

 

Securities and Exchange Commission

 

100 F Street, N.E.

 

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by NOTABLE LABS, LTD. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of NOTABLE LABS, LTD. dated January 30, 2024. We agree with the statements concerning our Firm contained therein.

 

Very truly yours,

 

Tel-Aviv, Israel /s/ Kesselman & Kesselman
February 2, 2024 Certified Public Accountants (Isr.)
  A member firm of PricewaterhouseCoopers International Limited

 

 

v3.24.0.1
Cover
Jan. 30, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 30, 2024
Entity File Number 001-36581
Entity Registrant Name NOTABLE LABS, LTD.
Entity Central Index Key 0001603207
Entity Incorporation, State or Country Code L3
Entity Address, Address Line One 320 Hatch Drive
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code (415)
Local Phone Number 851-2410
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, par value NIS 0.35 each
Trading Symbol NTBL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vascular Biogenics Charts.
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vascular Biogenics Charts.